CN1649898A - 新型肽及其的治疗中的应用 - Google Patents

新型肽及其的治疗中的应用 Download PDF

Info

Publication number
CN1649898A
CN1649898A CNA038100606A CN03810060A CN1649898A CN 1649898 A CN1649898 A CN 1649898A CN A038100606 A CNA038100606 A CN A038100606A CN 03810060 A CN03810060 A CN 03810060A CN 1649898 A CN1649898 A CN 1649898A
Authority
CN
China
Prior art keywords
seq
peptide
leu
cytokine
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038100606A
Other languages
English (en)
Chinese (zh)
Inventor
让－弗兰西斯·萨古里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxconsulting
Original Assignee
Vaxconsulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxconsulting filed Critical Vaxconsulting
Publication of CN1649898A publication Critical patent/CN1649898A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA038100606A 2002-04-10 2003-04-09 新型肽及其的治疗中的应用 Pending CN1649898A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/04464 2002-04-10
FR0204464A FR2838444B1 (fr) 2002-04-10 2002-04-10 Nouveaux peptides et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CN1649898A true CN1649898A (zh) 2005-08-03

Family

ID=28459716

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038100606A Pending CN1649898A (zh) 2002-04-10 2003-04-09 新型肽及其的治疗中的应用

Country Status (20)

Country Link
US (6) US7393523B2 (enExample)
EP (3) EP2314311B1 (enExample)
JP (1) JP2005530723A (enExample)
KR (1) KR101101004B1 (enExample)
CN (1) CN1649898A (enExample)
AT (1) ATE526985T1 (enExample)
AU (1) AU2003260031B2 (enExample)
CA (1) CA2480996C (enExample)
DK (1) DK2314311T3 (enExample)
ES (2) ES2375053T3 (enExample)
FR (1) FR2838444B1 (enExample)
IL (1) IL164429A0 (enExample)
MA (1) MA27191A1 (enExample)
MX (1) MXPA04009841A (enExample)
NZ (1) NZ536351A (enExample)
RU (1) RU2326125C2 (enExample)
SI (1) SI2314311T1 (enExample)
TN (1) TNSN04200A1 (enExample)
WO (1) WO2003084979A2 (enExample)
ZA (1) ZA200408451B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216323B (zh) * 2008-11-17 2016-08-03 哥本哈根大学 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
CN110133300A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
CN111727374A (zh) * 2017-10-13 2020-09-29 纳米智能生物医学工程有限公司 Grp78衍生肽用于鉴定高效干细胞
CN114026114A (zh) * 2019-05-10 2022-02-08 比姆约有限公司 用于治疗再灌注损伤的bnip3肽

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US7892558B2 (en) 2004-02-27 2011-02-22 Vaxconsulting Isolated TNF-alpha peptide and pharmaceutical composition thereof
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
ES2602436T3 (es) 2010-05-11 2017-02-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Inhibidor basado en péptido de la activación de interleucina 10 o STAT-3
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JP2018521016A (ja) * 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン
EP4486387A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
CZ283050B6 (cs) * 1989-12-20 1997-12-17 Schering Corporation Polypeptid, jeho subsekvence a jejich použití
EP0521918A4 (en) * 1990-03-19 1993-05-05 Peptide Technology Ltd Anti-tumour peptides
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
CA2139571C (en) * 1992-07-07 2006-11-14 Eleanor N. Fish Interferon receptor binding peptides
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
EP1005354A4 (en) * 1997-02-07 2002-05-15 Univ Jefferson PEPTIDE MIMETICS OF THE GAMMA CHAIN OF CYTOKINE RECEPTORS
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
NZ513507A (en) * 1999-02-08 2003-08-29 Medvet Science Pty Ltd Cytokine-binding domain
KR20010102556A (ko) * 1999-03-11 2001-11-15 추후제출 암 및 과증식성 장애의 치료 조성물 및 치료방법
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216323B (zh) * 2008-11-17 2016-08-03 哥本哈根大学 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
CN110133300A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
CN110133300B (zh) * 2012-03-18 2022-02-25 镜株式会社 疾病样品分析装置、分析系统及分析方法
CN111727374A (zh) * 2017-10-13 2020-09-29 纳米智能生物医学工程有限公司 Grp78衍生肽用于鉴定高效干细胞
CN111727374B (zh) * 2017-10-13 2024-02-20 纳米智能生物医学工程有限公司 Grp78衍生肽用于鉴定高效干细胞
CN114026114A (zh) * 2019-05-10 2022-02-08 比姆约有限公司 用于治疗再灌注损伤的bnip3肽

Also Published As

Publication number Publication date
US7641895B2 (en) 2010-01-05
EP2314312A2 (fr) 2011-04-27
WO2003084979A2 (fr) 2003-10-16
EP1492814B1 (fr) 2011-10-05
RU2004132871A (ru) 2005-09-20
EP2314311B1 (fr) 2015-07-15
US20120321652A1 (en) 2012-12-20
SI2314311T1 (sl) 2015-12-31
US7393523B2 (en) 2008-07-01
ATE526985T1 (de) 2011-10-15
MXPA04009841A (es) 2005-06-17
ES2550030T3 (es) 2015-11-04
TNSN04200A1 (fr) 2007-03-12
KR20040108709A (ko) 2004-12-24
FR2838444A1 (fr) 2003-10-17
RU2326125C2 (ru) 2008-06-10
WO2003084979A3 (fr) 2004-04-08
DK2314311T3 (en) 2015-10-12
CA2480996A1 (fr) 2003-10-16
US8147819B2 (en) 2012-04-03
KR101101004B1 (ko) 2011-12-29
FR2838444B1 (fr) 2016-01-01
MA27191A1 (fr) 2005-01-03
EP2314311A2 (fr) 2011-04-27
EP1492814A2 (fr) 2005-01-05
IL164429A0 (en) 2005-12-18
JP2005530723A (ja) 2005-10-13
AU2003260031B2 (en) 2009-10-29
AU2003260031A1 (en) 2003-10-20
US20060241286A1 (en) 2006-10-26
ZA200408451B (en) 2006-01-25
EP2314311A3 (fr) 2011-08-17
US20080260689A1 (en) 2008-10-23
US20110171169A1 (en) 2011-07-14
ES2375053T3 (es) 2012-02-24
US20100150957A1 (en) 2010-06-17
EP2314312A3 (fr) 2011-08-31
US7892529B2 (en) 2011-02-22
CA2480996C (fr) 2016-06-21
US8529881B2 (en) 2013-09-10
US20120121627A1 (en) 2012-05-17
US8277792B2 (en) 2012-10-02
NZ536351A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
CN1185348C (zh) 嵌合白细胞介素－6可溶性受体/配体蛋白质及其应用
CN1671423A (zh) 新型嵌合cd154
CN1214115C (zh) 由作为靶特异前体药物的抗体－细胞因子－细胞因子抑制剂(选择因子)组成的融合蛋白质
CN1649898A (zh) 新型肽及其的治疗中的应用
HK1039283A1 (en) Powdery preparation for mucosal administration containing polymeric medicine
CN1256147C (zh) Cd8作为细胞免疫系统的抑制剂
CN1764723A (zh) 白细胞介素－18突变体、其制品及应用
CN1241638C (zh) Ifnar2/ifn复合物
CN1195859C (zh) 修饰化人源粒细胞－集落刺激因子及其制备方法
CN1543504A (zh) 疫苗
CN1679919A (zh) 白细胞介素－1受体拮抗剂的细胞内同种型
CN1285381C (zh) 多发性硬化症治疗中所用的趋化因子突变体
CN1956997A (zh) 嵌合型可溶性超il－11和其应用
CN1201006C (zh) 高亲和性白细胞介素－4突变蛋白质
CN1741818A (zh) 线虫多肽佐剂
CN1726283A (zh) 利用c4bp支架制备多聚体融合蛋白
CN1718243A (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
CN1158387C (zh) 编码l.infantum的四种蛋白质的抗原决定簇的嵌合基因
CN1626554A (zh) 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
CN1730491A (zh) 猫ω干扰素及其编码基因与应用
CN1186448C (zh) 重组人α胸腺素原－白介素2基因及其表达、应用
CN1284854C (zh) 用于预防结核病和免疫治疗的嵌合型dna疫苗
CN101052415A (zh) 用于治疗和预防炎性疾病的方法和组合物
CN1778930A (zh) 激发机体抗鸡球虫感染的融合基因及其编码蛋白与应用
CN1737147A (zh) 热休克蛋白65－多表位乙型肝炎病毒核心抗原重组融合蛋白（HSP65－HBcAg）

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20050803